News
TECH
62.12
-0.14%
-0.09
Navigating 4 Analyst Ratings For Bio-Techne
Bio-Techne (NASDAQ:TECH) is a life sciences manufacturer. The company has a 12-month price target of $77.25. 4 analysts have released ratings for bio-techne in the past three months. The firm has a positive revenue growth rate of 0.37% over the past year.
Benzinga · 2d ago
Bio-Techne Price Target Cut to $82.00/Share From $85.00 by Deutsche Bank
Dow Jones · 2d ago
Bio-Techne Is Maintained at Buy by Deutsche Bank
Dow Jones · 2d ago
Deutsche Bank Maintains Buy on Bio-Techne, Lowers Price Target to $82
Benzinga · 2d ago
U.S. RESEARCH ROUNDUP- Builders Firstsource, Eli Lilly, Northern Trust
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Builders Firstsource, Eli Lilly, Northern Trust and Abbott Laboratories are among those. Alphabet Inc raises its target price to $165 from $160. TenX Genomics Inc, a maker of DNA sequencing equipment, is downgraded to hold from sell.
Reuters · 2d ago
BIO-TECHNE CORP <TECH.O>: DEUTSCHE BANK CUTS TARGET PRICE TO $82 FROM $85
Reuters · 2d ago
Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate
The projected fair value for Bio-Techne Corporation is US$50.55 based on 2 Stage Free Cash Flow to Equity Current share price of US$66.73 suggests Bio- techne is potentially 32% overvalued. Our fair value estimate is 37% lower than Bio-techne's analyst price target. We will use the Discounted Cash Flow model to estimate the stock's intrinsic value.
Simply Wall St · 5d ago
Weekly Report: what happened at TECH last week (0408-0412)?
Weekly Report · 5d ago
Cardinal Health, Cigna, Merck among top healthcare Quant picks ahead of Q1 earnings
Healthcare Cardinal Health, Cigna, Merck among top healthcare Quant picks ahead of Q1 earnings. The S&P 500’s health care sector is the third lowest scored sector by the SA Quant rating system. Cardinal Health has the highest score of 4.87.
Seeking Alpha · 04/11 14:33
RBC Capital Reaffirms Their Hold Rating on Bio-Techne (TECH)
TipRanks · 04/09 01:46
Weekly Report: what happened at TECH last week (0401-0405)?
Weekly Report · 04/08 09:16
BIO-TECHNE CORP <TECH.O>: RBC RAISES TARGET PRICE TO $79 FROM $75
Reuters · 04/08 06:24
Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Bio-Techne is a life science tools and services company focused on the development and sale of reagents and consumables for life science research. The company's focus on the stable and lucrative life science market has led to above-average growth and profitability compared to diagnostic companies. Bio- techne has exhibited strong financial performance, with high profit margins and low leverage. Healthcare is a strong sector for secular growth, but life science is more stable than diagnostics.
Seeking Alpha · 04/04 12:43
Buy Rating Affirmed for Bio-Techne Amid Market Recovery and Strategic Positioning
TipRanks · 04/04 09:45
Weekly Report: what happened at TECH last week (0325-0329)?
Weekly Report · 04/01 09:16
Those who invested in Bio-Techne (NASDAQ:TECH) five years ago are up 45%
Bio-Techne Corporation (NASDAQ:TECH) has a share price rise of 42% over five years. The stock is actually down 5.1% in the last year. The company has managed to grow its earnings per share at 17% a year over the last decade. But the stock is below the market return over the same period. It could be worth looking at the company's fundamentals to see if Bio- techne is undervalued.
Simply Wall St · 03/31 12:12
TECH Quantitative Stock Analysis
NASDAQ · 03/30 17:05
Weekly Report: what happened at TECH last week (0318-0322)?
Weekly Report · 03/25 09:16
Revvity: Enter Now As Reorganization Takes Shape
Revvity, Inc. Is a major laboratory instrument and service provider to the healthcare industry. The company has historically underperformed compared to its peers in terms of profit generation and growth. Revvity has implemented a business restructuring plan and aims to drive differentiation through inorganic investments in high-margin areas. Over the past 20 years the company has returned 10.5% per year for investors.
Seeking Alpha · 03/21 15:27
Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader
Cytek Biosciences is a leading cellular analysis instrument maker with a focus on the Aurora flow cytometry platform. Despite a downturn in the healthcare market, Cytek has maintained revenue growth above 15% since IPO. Cytek's technological advantage, broadening ecosystem, and potential in the clinical and biopharma space contribute to the positive outlook.
Seeking Alpha · 03/20 08:33
More
Webull provides a variety of real-time TECH stock news. You can receive the latest news about Bio-Techne Corp through multiple platforms. This information may help you make smarter investment decisions.
About TECH
Bio-Techne Corporation is a global life sciences company. The Company is engaged in providing tools and bioactive reagents for the research and clinical diagnostic communities. It operates through two segments: Protein Sciences and Diagnostics and Genomics. Its Protein Sciences segment develops and manufactures biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.